MLSS Stock Overview A biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Milestone Scientific Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Milestone Scientific Historical stock prices Current Share Price US$0.88 52 Week High US$1.10 52 Week Low US$0.52 Beta 1.09 1 Month Change -11.11% 3 Month Change -3.35% 1 Year Change 27.55% 3 Year Change -57.28% 5 Year Change -36.69% Change since IPO -93.82%
Recent News & Updates
Consensus EPS estimates fall by 25% Nov 21
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 17
Milestone Scientific Inc. Announces CEO Changes Nov 15
Milestone Scientific Expands Commercial Rollout of the CompuFlo Epidural System with Esteemed Pain Management Physician Dr. Elbaz At Hudson Specialty Care Nov 02
Milestone Scientific Inc. Announces Commercial Rollout of Compuflo® Epidural System At Iheal Pain Center Following Medicare Price Assignment Oct 03
Founder & Vice Chairman recently sold US$135k worth of stock Aug 23 See more updates
Consensus EPS estimates fall by 25% Nov 21
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 17
Milestone Scientific Inc. Announces CEO Changes Nov 15
Milestone Scientific Expands Commercial Rollout of the CompuFlo Epidural System with Esteemed Pain Management Physician Dr. Elbaz At Hudson Specialty Care Nov 02
Milestone Scientific Inc. Announces Commercial Rollout of Compuflo® Epidural System At Iheal Pain Center Following Medicare Price Assignment Oct 03
Founder & Vice Chairman recently sold US$135k worth of stock Aug 23
Second quarter 2024 earnings released: EPS: US$0.003 (vs US$0.031 loss in 2Q 2023) Aug 16
Milestone Scientific Inc. Secures Key Patent Approvals in the U.S. and Europe Jul 31
Milestone Scientific Announces Medicare Price Assignment for the CompuFlo® Epidural System in Texas, Pennsylvania, New Jersey, Maryland, Colorado, Oklahoma, Louisiana, Arkansas, Mississippi, New Mexico, District of Columbia, and Delaware Jul 23
Milestone Scientific Inc. Announces Favorable Medicare Pricing for Its CompuFlo® Epidural System Within First JMAC Region Covering Florida Jul 10 Milestone Scientific Receives Regulatory Approval to Market Compuflo Epidural System in Brazil Jun 18
Milestone Scientific Inc., Annual General Meeting, Jul 16, 2024 Jun 08
First quarter 2024 earnings: EPS in line with expectations, revenues disappoint May 17
Consensus revenue estimates decrease by 10% Apr 05
Full year 2023 earnings: EPS and revenues miss analyst expectations Mar 31 Milestone Scientific Inc. has completed a Follow-on Equity Offering in the amount of $3.00195 million. Dec 11
New minor risk - Shareholder dilution Dec 11 Milestone Scientific Inc. has filed a Follow-on Equity Offering. Dec 09
Consensus revenue estimates decrease by 13% Nov 21
New major risk - Financial position Nov 17
Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint Nov 17
Director notifies of intention to sell stock Oct 24
Less than half of directors are independent Sep 14
Milestone Scientific Inc. Appoints Didier Demesmin to Board of Directors Sep 13
Milestone Scientific Inc. Announces Resignation of Peter J. Milligan as Chief Financial Officer, Effective September 1, 2023 Aug 25
Consensus EPS estimates fall by 29%, revenue upgraded Aug 21
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 15
New minor risk - Share price stability Aug 13
Consensus estimates of losses per share improve by 12% May 17
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 12
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 02
Milestone Scientific Inc. Announces the Appointment of Peter Milligan as the Chief Financial Officer Feb 07
Milestone Scientific Inc. Announces Board Changes Jan 07
Milestone Scientific Inc. Appoints Neal Goldman as Chairman of the Board of Directors Jan 06
Leonard M. Schiller Tenders His Resignation to Milestone Scientific Inc. as A Director Dec 09
Insufficient new directors Nov 16
Consensus forecasts updated Aug 22
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 17
Insufficient new directors Jun 01
Milestone Scientific Inc. Reports Commencement of Sales of its CompuFlo(R) Epidural Instrument Disposables at a Leading Veterinary and Academic Institution May 28
First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat May 18
Insufficient new directors May 02
Milestone Scientific Inc., Annual General Meeting, Jun 13, 2022 May 02
Price target decreased to US$4.00 Apr 27
Price target decreased to US$4.00 Apr 07
Founder notifies of intention to sell stock Apr 07
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Apr 02
Founder notifies of intention to sell stock Mar 05
Milestone Scientific Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021 Jan 12
Founder exercised options to buy US$268k worth of stock. Dec 06
Third quarter 2021 earnings released: US$0.029 loss per share (vs US$0.023 loss in 3Q 2020) Nov 15
Founder exercised options to buy US$417k worth of stock. Nov 15
Independent Chairman of the Board notifies of intention to sell stock Sep 21
Independent Chairman of the Board recently sold US$86k worth of stock Sep 18
Consensus EPS estimates fall to -US$0.11 Aug 20
Second quarter 2021 earnings released: US$0.039 loss per share (vs US$0.056 loss in 2Q 2020) Aug 14
Chief Financial Officer Scott Kahn has left the company Jul 13 Milestone Scientific Inc.(NYSEAM:MLSS) dropped from Russell 3000E Value Index
Consensus forecasts updated May 21
First quarter 2021 earnings released: US$0.015 loss per share (vs US$0.032 loss in 1Q 2020) May 16
Consensus revenue estimates increase to US$10.3m May 04
Full year 2020 earnings released: US$0.12 loss per share (vs US$0.17 loss in FY 2019) Apr 02
Milestone Scientific Receives Notice of Allowance for European Patent Related to Combination of Nerve Stimulation and Dps Dynamic Pressure Sensing Technology® to Optimize Needle Tip Location in Ultrasound-Guided Pnb Procedures Mar 11
Milestone Scientific Inc. Commences Sales of CompuFlo® / CathCheck™ Disposables to the Nationally Recognized Medical University of South Carolina Mar 04
New 90-day high: US$4.13 Mar 03
Did You Miss Milestone Scientific's (NYSEMKT:MLSS) Whopping 317% Share Price Gain? Feb 23
Independent Chairman of the Board notifies of intention to sell stock Feb 19
Analysts update estimates Feb 19
Independent Chairman of the Board recently sold US$169k worth of stock Feb 19
Milestone Scientific Inc. Adds Three Additional Premier Distributors Providing Robust U.S. Coverage and A New Distributor in Canada for the Company’S Dental Instrument Feb 17
Milestone Scientific Inc. Signs Two Additional Distribution Agreements with Atlanta Dental and Nashville Dental for its Wand Single Tooth Anesthesia System Feb 10
New 90-day high: US$3.48 Feb 09
Director recently sold US$215k worth of stock Feb 05
Milestone Scientific Inc. Receives Notice of Allowance for U.S Patent Related to Compuflo® Disposables Jan 22
New 90-day high: US$2.90 Jan 20
Milestone Scientific Inc. Announces It Has Begun Implementing Three-Year Strategy to Expand the World-Wide Global Dental Market Jan 20
Milestone Scientific Inc. Announces Agreement with Bitmedical AG to Distribute the CompuFlo® Epidural Instrument Across Austria and Switzerland Jan 12
Milestone Scientific Inc. Raises Revenue Guidance for Fourth Quarter 2020 Jan 08
Founder exercised options to buy US$183k worth of stock. Jan 07
Milestone Scientific Inc. Announces Entrée into the Nationally Recognized University of Texas Medical Branch at Galveston with its CompuFlo Disposables Jan 05
New 90-day high: US$2.31 Jan 05
CFO & COO recently sold US$59k worth of stock Jan 02
CFO & COO recently sold US$60k worth of stock Dec 19
Founder notifies of intention to sell stock Dec 18
New 90-day high: US$2.06 Dec 16
Here's What Milestone Scientific Inc.'s (NYSEMKT:MLSS) Shareholder Ownership Structure Looks Like Dec 15
Milestone Scientific Inc. Announces Appointment of Neil Goldman as Director Dec 13 Shareholder Returns MLSS US Medical Equipment US Market 7D -4.9% 0.8% 0.6% 1Y 27.6% 10.0% 23.7%
See full shareholder returns
Return vs Market: MLSS exceeded the US Market which returned 23.7% over the past year.
Price Volatility Is MLSS's price volatile compared to industry and market? MLSS volatility MLSS Average Weekly Movement 12.7% Medical Equipment Industry Average Movement 8.0% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.5% 10% least volatile stocks in US Market 3.1%
Stable Share Price: MLSS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MLSS's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Milestone Scientific Inc., a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic.
Show more Milestone Scientific Inc. Fundamentals Summary How do Milestone Scientific's earnings and revenue compare to its market cap? MLSS fundamental statistics Market cap US$68.55m Earnings (TTM ) -US$4.62m Revenue (TTM ) US$8.88m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) MLSS income statement (TTM ) Revenue US$8.88m Cost of Revenue US$2.44m Gross Profit US$6.43m Other Expenses US$11.05m Earnings -US$4.62m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.059 Gross Margin 72.48% Net Profit Margin -52.01% Debt/Equity Ratio 0%
How did MLSS perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/29 09:03 End of Day Share Price 2024/12/27 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Milestone Scientific Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Bruce Jackson Benchmark Company Anthony Vendetti Maxim Group Jon Hickman MDB Capital Group LLC
Show 3 more analysts 
